Kari Firestone is co-founder and Chair Emerita of Aureus Management, an investment firm that manages over $6 billion of assets for families, individuals, and non-profit entities. Previously, she spent 22 years at Fidelity Investments, most recently as a diversified fund manager of Destiny 1 Fund, the Large Cap Fund, Advisor Large Cap Fund and managing numerous sector funds, including Biotechnology, Health Care, and Media. Her Fidelity career began as an assistant fund manager to Peter Lynch on the Magellan Fund. She was twice named to the Institutional Investor “Best of the Buy Side” All Star team.
In 2022, Kari was named to the Forbes 50 Over 50 list of women, recognizing achievements occurring from age fifty and beyond.
Kari is a regular contributor on CNBC, where she appears on Half Time Report, Squawk Box, and Worldwide Exchange, and writes for the website CNBC.com. Ms. Firestone’s book, “Even the Odds: Sensible Risk Taking in Business, Investing, and Life” was published by Bibliomotion in 2016. She gave a TEDx talk on “Becoming a Sensible Risk-Taker.”
Ms. Firestone received a Bachelor of Arts degree in economics, magna cum laude, from Harvard College and an MBA from Harvard Business School. Ms. Firestone, serves as a Trustee Emerita at the Beth Israel Deaconess Medical Center, and is a member of the Boston Athletic Association. She serves on the board of directors of public companies Hamilton Thorne Ltd and Amylyx Pharmaceuticals.
Kari lives in Brookline, Massachusetts with her husband, David. They have four grown children, six grandchildren, and two Springer Spaniels. Kari is an avid runner, tennis player and golfer and plays jazz and blues piano.
What is Karen Firestone's net worth?
The estimated net worth of Karen Firestone is at least $897.28 thousand as of December 23rd, 2025. Firestone owns 63,100 shares of Amylyx Pharmaceuticals stock worth more than $897,282 as of February 9th. This net worth estimate does not reflect any other investments that Firestone may own. Learn More about Karen Firestone's net worth.
How do I contact Karen Firestone?
Has Karen Firestone been buying or selling shares of Amylyx Pharmaceuticals?
Karen Firestone has not been actively trading shares of Amylyx Pharmaceuticals within the last three months. Most recently, on Tuesday, December 23rd, Karen Firestone bought 8,100 shares of Amylyx Pharmaceuticals stock. The stock was acquired at an average cost of $12.45 per share, with a total value of $100,845.00. Following the completion of the transaction, the director now directly owns 63,100 shares of the company's stock, valued at $785,595. Learn More on Karen Firestone's trading history.
Who are Amylyx Pharmaceuticals' active insiders?
Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), Karen Firestone (Director), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Amylyx Pharmaceuticals?
In the last year, Amylyx Pharmaceuticals insiders bought shares 2 times. They purchased a total of 18,100 shares worth more than $137,845.00. In the last year, insiders at the sold shares 15 times. They sold a total of 298,096 shares worth more than $3,610,929.18. The most recent insider tranaction occured on January, 16th when CEO Joshua B Cohen sold 1,974 shares worth more than $27,300.42. Insiders at Amylyx Pharmaceuticals own 12.3% of the company.
Learn More about insider trades at Amylyx Pharmaceuticals. Information on this page was last updated on 1/16/2026.
